Innovative study brings next-generation genomic sequencing to more Ontario cancer patients

(Ontario Institute for Cancer Research) Understanding a cancer's genetics is key to selecting targeted therapies that are likely to be of the most benefit to a patient. The Ontario Institute for Cancer Research today announced a new study, called Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE). OCTANE will use next-generation genome sequencing technology to bring a unified molecular profiling approach to five Ontario cancer centers.